Healthcare Support Services

Softmax Co., Ltd. (Japan)

2540

3941

9853

3671

Yomeishu Sets Record Date for Potential EGM Linked to Reno Tender Offer and Privatization Plan

Tip Ranks

Yomeishu Seizo Co., Ltd.

Rengo Co., Ltd.

Ginza Renoir Co., Ltd

Yomeishu Sets Record Date for Potential EGM Linked to Reno Tender Offer and Privatization Plan

6535

2175

SMS Co., Ltd. (TSE:2175) is set to go ex-dividend in four days, with a dividend payment of JP¥29.50 per share on June 23. The stock has a trailing yield of 1.8% based on a current price of JP¥1646.00. The company pays out 35% of its earnings in dividends and 84% of its free cash flow, indicating a sustainable dividend. Earnings per share have grown by 8.9% over the last five years, and dividends have increased by 24% annually over the past decade. However, caution is advised due to potential risks associated with the stock.

Simplywall

i-mobile Co., Ltd.

SMS Co., Ltd.

SMS Co., Ltd. (TSE:2175) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

7839

4202

1499

3681

3042

Polyplastics Co., Ltd.'s DURACON(R) POM resin has been adopted in a new crawler track transport system by CuboRex Co., Ltd. This innovative system enhances efficiency at factory and construction sites, outperforming traditional caster-equipped carts. DURACON(R) POM's high load-bearing capacity and excellent friction properties make it ideal for heavy-duty material handling. The system reduces operational strain and improves maneuverability, promising significant potential in the Japanese market and beyond. It allows for cost-effective upgrades to existing equipment, enhancing safety and operational efficiency across various industries.

prnewswire

Shoei Co. Ltd. (7839)

Daicel Corporation

Mitsubishi UFJ Financial Group, Inc.

V-cube, Inc.

SecuAvail, Inc.

01:00 ETPolyplastics' DURACON(R) POM Adopted for Ground-breaking Crawler Transport System

2181

2721

Japan Eyewear Holdings Co., Ltd. reported an 11.8% increase in consolidated revenue to ¥18.64 billion for FY2026, with operating profit also rising 11.8% to ¥5.96 billion. Despite a 5.3% drop in profit attributable to owners, the company raised its annual dividend by 27% to ¥84 per share. For FY2027, it forecasts a 10.5% revenue growth to ¥20.6 billion and a 16.3% increase in profit. The stock has a Buy rating with a price target of ¥2269.00.

PERSOL HOLDINGS CO. LTD.

J-Holdings Corp. (Japan)

Japan Eyewear Lifts Revenue and Dividend, Forecasts Double-Digit Profit Growth

4528

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

ONO Pharmaceutical Co., Ltd.

Curatis and Neupharma sign development agreement for corticorelin in Japan

6678

4570

ImmunoForge Co., Ltd. will participate in Bio-Europe Spring 2026 in Lisbon to engage in strategic meetings with global pharmaceutical companies and investors. The company aims to discuss its proprietary BBB Shuttle platform, LMT15, and out-licensing of its Phase 2 drugs, PF1801 and PF1804. ImmunoForge is focused on promoting collaboration and technology transfer, particularly regarding its long-acting ELP platform and CNS-targeted drug development. The company is currently accepting meeting requests for the event.

Techno Medica Co., Ltd.

Immuno-Biological Laboratories Co., Ltd.

04:58 ETImmunoForge to Conduct Strategic Partnering at Bio-Europe Spring 2026

i-mobile Co., Ltd. (JP:6535) has announced its FY2026 Q2 results, highlighting its corporate philosophy and vision focused on innovative businesses. The company aims to enhance user experiences through internet marketing, emphasizing its core values of "Smile, Growth, Team." The latest analyst rating for i-mobile stock is a Buy, with a price target of Yen581.00. i-mobile operates in the internet marketing industry and is committed to building future-oriented businesses centered on digital advertising.

i-mobile Highlights Vision and Values Alongside FY2026 Q2 Results

4886

AnnJi Pharmaceutical Co., Ltd. participated in the 2026 KDA Conference, presenting advancements in AJ201, a potential first-in-class therapy for Spinal and Bulbar Muscular Atrophy (SBMA). The company shared promising Phase 2 clinical results and unveiled the design for a global Phase 3 trial aimed at evaluating AJ201's efficacy and safety. AnnJi also hosted a Patient & Family Forum to engage with the SBMA community and announced the formation of a Patient Advisory Council to optimize trial design. The company remains committed to addressing the unmet needs of SBMA patients.

MorningStar

ASKA Pharmaceutical Holdings Co., Ltd.

Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference

Softmax Co., Ltd. (Japan)(3671.JP)

Yomeishu Sets Record Date for Potential EGM Linked to Reno Tender Offer and Privatization Plan

SMS Co., Ltd. (TSE:2175) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

01:00 ETPolyplastics' DURACON(R) POM Adopted for Ground-breaking Crawler Transport System

Japan Eyewear Lifts Revenue and Dividend, Forecasts Double-Digit Profit Growth

Curatis and Neupharma sign development agreement for corticorelin in Japan